Skip to main content
. 1999 Aug 17;96(17):9839–9844. doi: 10.1073/pnas.96.17.9839

Figure 4.

Figure 4

Analysis of active form of recombinant vCXC-1 and its effects on human PBN. (A) Heterologous desensitization profiles of listed chemokines on PBN. (Left) T23 form of vCXC-1 added as initial agonist, followed 60 sec later by other human chemokines, as listed. (Right) Human chemokines added first, followed by the T23 form of vCXC-1. (B) Cytoplasmic calcium induction by Y18 and T23 forms of vCXC-1; comparison with human IL-8 and gro α [chemokine (in nM) is indicated on the right of each data set].